DBV Technologies ADR(DBVT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.02 | Insider Own | 13.77% | Shs Outstand | 62.8M | Perf Week | -2.67% |
| Market Cap | 0.60B | Forward P/E | - | EPS next Y | 36.12% | Insider Trans | -0.01% | Shs Float | 54.2M | Perf Month | -15.34% |
| Enterprise Value | 0.45B | PEG | - | EPS next Q | -0.23 | Inst Own | 40.56% | Short Float | 1.61% | Perf Quarter | -30.12% |
| Income | -0.21B | P/S | - | EPS this Y | -4.37% | Inst Trans | 81.41% | Short Ratio | 2.34 | Perf Half Y | -52.24% |
| Sales | 0.00B | P/B | 4.01 | EPS next 5Y | 45.77% | ROA | -127.24% | Short Interest | 0.87M | Perf YTD | -50.5% |
| Book/sh | 2.36 | P/C | 3.6 | EPS past 3/5Y | 5.33% 18.68% | ROE | -205.84% | 52W High | -63.76% ($26.18) | Perf Year | -32.65% |
| Cash/sh | 2.64 | P/FCF | - | Sales past 3/5Y | - | ROIC | -133.5% | 52W Low | 9.97% ($8.63) | Perf 3Y | -9.62% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 42.37% | Gross Margin | - | Volatility(W/M) | 8.04% 5.6% | Perf 5Y | -68.68% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.61 | Perf 10Y | -97.3% |
| Dividend Ex-Date | - | Quick Ratio | 3.24 | EPS Q/Q | 40.8% | Profit Margin | - | RSI (14) | 39.68 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.24 | Sales Q/Q | - | SMA20 | -1.75% ($9.66) | Beta | -0.88 | Target Price | $41.92 |
| Payout | - | Debt/Eq | 0.15 | Earnings | 2026/10/28 | SMA50 | -17.68% ($11.53) | Rel Volume | 1.1 | Prev Close | $10.29 |
| Employees | 125 | LT Debt/Eq | 0.05 | EPS/Sales Surpr. | 46.15% 220% | SMA200 | -44.02% ($16.95) | Avg Volume(3M) | 0.37M | Price | $9.49 |
| IPO | 2014/10/22 | Option/Short | Yes/Yes | Trades | 1694 | Volume | 410,568 | Change | -7.77% |
DBV Technologies is a late-stage clinical biopharmaceutical company developing a skin patch to treat food allergies. Its core platform, Viaskin, is a non-invasive epicutaneous immunotherapy that delivers small amounts of allergens to the immune system through intact skin, with the peanut allergy patch Viaskin Peanut as its lead candidate.
Over the past 1 year, on the lower side
64% below its 1-year high.
Traded about as much as usual. That is 110% of its average volume.
DBVT has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -4.4% this year.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -68.7%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 40.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #200 of 597 in the industry
Based on market cap of $596M.
BCAX#198 Bicara Therapeutics Inc $604M PER - 
NVCT#199 Nuvectis Pharma Inc $603M PER - DBVT#200 DBV Technologies ADR $596M PER - 
CLYM#201 Climb Bio Inc $589M PER - 
ACRS#202 Aclaris Therapeutics Inc $584M PER - 
FAQ
What kind of company is DBVT?
DBVT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of DBVT?
The market cap of DBVT is approximately $596M, ranking 3,002 within its sector.
What is the 52-week high and low for DBVT?
DBVT has recorded a 52-week high of $26.18 and a low of $8.63.
